Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Conditions

• Plaque Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• envudeucitinib — DRUG
  Oral tablet

Study Details

This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.

Key Dates

Start date

Jan 17, 2023

Status verified

Jun 2026

Primary completion

Dec 1, 2026

Completion

Dec 30, 2026

Study Design

Enrollment

165 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: envudeucitinib Dose Level 1
  envudeucitinib administered as an oral tablet
• Experimental: envudeucitinib Dose Level 2
  envudeucitinib administered as an oral tablet

Primary Outcome Measure

To assess the safety and tolerability of long-term ESK-001 treatment [ Time Frame: Approximately 3 years ]

Locations (28)

Find similar trials in Birmingham, AL

Related Studies

• Understanding Participation Habits Among Plaque Psoriasis Patients
  Not Yet Recruiting · Power Life Sciences Inc. · San Francisco, California
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  PHASE3 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
  PHASE1 · Recruiting · Ascletis Pharma (China) Co., Limited · Miami, Florida
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  PHASE3 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama